Compare AbbVie Inc (ABBV) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Tyson Foods, Inc. — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Tyson Foods, Inc. trades at $56.65 (market cap $20.11B). The key difference: AbbVie Inc is far larger — about 21.8× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| ABBV | TSN | |
|---|---|---|
Market Cap | $438.19B | $20.11B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $68.75 |
52-Week Low | $197.38 | $50.72 |
Enterprise Value | $502.45B | $27.37B |
Dividend Yield | 2.79% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Tyson Foods (TSN) trades at $58.04, down 0.85% on the day, with a bearish technical signal and mixed earnings history. The company reported Q3 2026 EPS of $0.99, beating estimates, but revenue trends are pressured by beef segment losses. Valuation metrics show a P/E of 35.83 and P/S of 0.37, with a consensus analyst price target of $68.50. Recent news highlights debt tender offers and a maintained quarterly dividend of $0.51.
The outlook is cautious due to persistent beef margin challenges, though chicken and prepared foods provide stability. Investment appeal lies in the discounted valuation and dividend yield, but risks include volatile input costs and competitive pressures. Analyst sentiment is divided, with 50% buy ratings but bearish technical indicators suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
